



WHAT IS CLAIMED IS:

1. Compounds of the general formulae D1



(a)



(b)

D1

wherein



- all substituted and unsubstituted, condensed and non-condensed homocyclic and heterocyclic basic structures having more than six members in the ring (a) as well as having less than five members in the ring (a) are represented;
- the basic structures may contain double bonds;
- Y represents O, S or NR<sub>4</sub>;
- R<sub>2</sub> symbolizes the substitution of the cyclic basic structure in (a) and may represent one or several substituents;
- R<sub>1</sub> to R<sub>6</sub> may be identical or different and are selected from the group consisting of hydrogen, unsubstituted or substituted, straight chain or branched C<sub>1</sub>- to C<sub>12</sub> alkyl, C<sub>2</sub>- to C<sub>12</sub> alkenyl and C<sub>2</sub>- to C<sub>12</sub> alkynyl, hydr-oxy, thiol, C<sub>1</sub>- to C<sub>12</sub> alkoxy, C<sub>1</sub>- to C<sub>12</sub> alkylthio, unsubstituted or substituted, uncondensed or condensed aryl and cycloalkyl optionally containing one or several hetero atoms from the group N, O, P and S, unsubstituted or substituted amino, unsubstituted or substituted carbonyl, unsubstituted or substituted thiocarbonyl and unsubstituted or substituted imino; and
- the heteroaromatic or heterocyclic residues are bound to the basic structure of the general formula D1 via a C atom or a hetero atom;



P29678.S01

and tautomers, stereoisomers of the compounds of the general formula D1 and pharmaceutically acceptable salts, salt derivatives, tautomers and stereoisomers thereof, for a use in the medical field.


2. The compounds of the general formula D1 according to claim 1 for a use in the medical field, namely compounds for example, but not exclusively, selected from the following group D1 according to Table 1, and tautomers, stereoisomers of said compounds and pharmaceutically acceptable salts, salt derivatives, tautomers and stereoisomers thereof:

**Table 1:**

Compound ID.	Structure
D1.001	
D1.002	

D1.003	
D1.004	

### 3. Compounds of the general formula D2



wherein

- Y1 and Y2 may be identical or different and represent O, S or NR<sub>3</sub>;
- R1 to R4 may be identical or different and are selected from the group consisting of hydrogen, unsubstituted or substituted, straight chain or branched C<sub>1</sub>- to C<sub>12</sub> alkyl, C<sub>2</sub>- to C<sub>12</sub> alkenyl and C<sub>2</sub>- to C<sub>12</sub> alkynyl, hydr-oxy, thiol, C<sub>1</sub>- to C<sub>12</sub> alkoxy, C<sub>1</sub>- to C<sub>12</sub> alkylthio, unsubstituted or substituted, uncondensed or condensed aryl and cycloalkyloptionally containing one or several hetero at-

P29678.S01


oms from the group N, O, P and S, unsubstituted or substituted amino, unsubstituted or substituted carbonyl, unsubstituted or substituted thiocarbonyl and unsubstituted or substituted imino; and

- the heteroaromatic or heterocyclic residues are bound to the basic structure of the general formula D2 via a C atom or a hetero atom;







and tautomers, stereoisomers of the compounds of the general formula D2 and pharmaceutically acceptable salts, salt derivatives, tautomers and stereoisomers thereof, for a use in the medical field.

4. The compounds of the general formula D2 according to claim 3 for a use in the medical field, namely compounds for example, but not exclusively, selected from the following group D2 according to Table 2, and tautomers, stereoisomers of said compounds and pharmaceutically acceptable salts, salt derivatives, tautomers and stereoisomers thereof:


**Table 2:**

Compound ID.	Structure
D2.001	

P29678.S01

D2.003	
D2.004	
D2.005	
D2.006	
D2.007	
D2.008	

### 5. Compounds of the general formulae D3



wherein




- X and Z independent of each other represent CH, CR<sub>3</sub> or N;
- the partial rings may be substituted or unsubstituted, condensed or noncondensed and may contain zero to three double bonds and zero to four hetero atoms and hetero atom-containing groups according to the definitions for X and Z;
- R<sub>1</sub> to R<sub>4</sub> may be identical or different and are selected from the group consisting of hydrogen, unsubstituted or substituted, straight chain or branched C<sub>1</sub>- to C<sub>12</sub> alkyl, C<sub>2</sub>- to C<sub>12</sub> alkenyl and C<sub>2</sub>- to C<sub>12</sub> alkynyl, hydroxy, thiol, C<sub>1</sub>- to C<sub>12</sub> alkoxy, C<sub>1</sub>- to C<sub>12</sub> alkylthio, unsubstituted or substituted, uncondensed or condensed aryl and cycloalkyl optionally containing one or several hetero atoms from the group N, O, P and S, unsubstituted or substituted amino, unsubstituted or substituted carbonyl, unsubstituted or substituted thiocarbonyl and unsubstituted or substituted imino; and
- the heteroaromatic or heterocyclic residues are bound to the basic structure of the general formula D2 via a C atom or a hetero atom; the ring systems of the basic structures may contain zero to three double bonds;






and tautomers, stereoisomers of the compounds of the general formula D3 and pharmaceutically acceptable salts, salt derivatives, tautomers and stereoisomers thereof, for a use in the medical field.

P29678.S01

6. The compounds of the general formula D3 according to claim 5 for a use in the medical field, namely compounds for example, but not exclusively, selected from the following group D3 according to Table 3, and tautomers, stereoisomers of said compounds and pharmaceutically acceptable salts, salt derivatives, tautomers and stereoisomers thereof:






**Table 3:**








Compound ID.	Structure
D3.001	
D3.002	
D3.003	





D3.004	
D3.005	
D3.006	
D3.007	
D3.008	







P29678.S01







D3.009	
D3.010	
D3.011	
D3.012	
D3.013	






D3.014	
D3.015	
D3.016	
D3.017	
D3.018	
D3.019	
D3.020	







D3.021	 <p>Chemical structure of 1-phenyl-2-(propionimidazol-2-yl)benzimidazole. It features a benzimidazole core with a phenyl group at position 1 and a propionimidazole group at position 2.</p>
D3.022	 <p>Chemical structure of 1-(4-chlorophenyl)-2-(4-hydroxybutyl)-3,4-dimethyl-1H-imidazo[1,2-a]pyrimidin-6(1H)-one. It features a fused imidazo[1,2-a]pyrimidin-6(1H)-one core with a 4-chlorophenyl group at position 1, a 4-hydroxybutyl group at position 2, and methyl groups at positions 3 and 4.</p>
D3.023	 <p>Chemical structure of 1-(2-nitrophenyl)-2-(2-phenylacetamido)benzimidazole. It features a benzimidazole core with a 2-nitrophenyl group at position 1 and a 2-phenylacetamido group at position 2.</p>
D3.024	 <p>Chemical structure of 1-(4-oxo-4,5,6,7-tetrahydrothiazolo[5,4-d]thiazine-2-yl)-2-phenyl-1H-imidazole. It features a fused thiazolo[5,4-d]thiazine-2(1H)-one core with a 2-phenyl-1H-imidazole group at position 1 and a 4-oxo-4,5,6,7-tetrahydrothiazine-2-yl group at position 2.</p>






D3.025	 <p>Chemical structure of 4-(4-(2-oxo-2-(propanoyloxy)ethyl)phenoxy)benzamide. It features a central benzamide group where the amide nitrogen is attached to a 4-(2-oxo-2-(propanoyloxy)ethyl)phenoxy group.</p>
D3.026	 <p>Chemical structure of 6,7-dimethoxy-1,2,3,4-tetrahydroquinoline. It consists of a benzene ring fused to a six-membered ring containing a nitrogen atom and two methoxy groups at the 6 and 7 positions.</p>
D3.027	 <p>Chemical structure of 1-methyl-2-((4-ethyl-1H-imidazo[4,5-b]pyridin-2-yl)azepan-1-yl)propan-1-one. It features a complex heterocyclic system with a pyridine ring fused to an imidazole ring, which is connected via an azepane ring to a propanone chain.</p>
D3.029	 <p>Chemical structure of a complex polycyclic molecule. It features a central benzene ring fused to a complex polycyclic system containing multiple methoxy groups and a lactone ring.</p>

P29678.S01







D3.030	
D3.031	
D3.032	
D3.033	
D3.034	
D3.035	

D3.037	
D3.038	
D3.039	
D3.040	
D3.042	







D3.043	
D3.044	
D3.045	
D3.046	
D3.047	
D3.048	







D3.049	 <chem>O=C(C(F)(F)F)Nc1ccc2c(c1)sc2C#N</chem>
D3.050	 <chem>O=C1c2ccccc2N1c3ccc(cc3)c4nc5c(nc4c5)cc(cc5c4)cc(F)c5cc([N+](=O)[O-])ccc5</chem>
D3.051	 <chem>O=C1N(c2ccccc2)C(=S)N1Cc3c[nH]c4ccccc34</chem>
D3.052	 <chem>COC(=O)c1nc2c(nc(=O)[nH]2)sc1C#N</chem>
D3.054	 <chem>CN1CCN(C1)c2nc3c(nc2c3)cc(cc3c2)cc(F)c3ccccc3</chem>










D3.055	
D3.056	
D3.057	
D3.058	
D3.059	
D3.060	





P29678.S01






D3.061	
D3.062	
D3.063	
D3.064	
D3.066	
D3.067	







D3.069	
D3.070	
D3.072	
D3.073	
D3.074	
D3.077	







•

D3.078	
D3.079	
D3.080	
D3.081	
D3.082	
D3.083	
D3.084	





D3.086	 <chem>CCOC(=O)c1c[nH]c2cc(F)ccc12NC(=O)CN1CCN(CC1)N2C(=O)N(C)C(=O)N2C</chem>
D3.087	 <chem>Clc1cc(Cl)cc(C(=O)NN=Cc2cc3c(cc2)OCC3)cc1</chem>
D3.088	 <chem>Cc1ccc(cc1)N2C(=O)c3sc(cc32)C4COC(C)(C)CC4</chem>
D3.089	 <chem>CC1=C(C(=O)N1C(=O)N2C(=O)N(C)C(=O)N2C)N3C(=O)N(C)C(=O)N3CC(O)COc4ccc(Cl)cc4</chem>





D3.091	
D3.092	
D3.093	
D3.094	
D3.095	





D3.096	
D3.097	
D3.098	
D3.099	
D3.100	
D3.101	

D3.102	
D3.103	
D3.104	
D3.105	
D3.106	
D3.107	



D3.108	
D3.109	
D3.110	
D3.111	

D3.112	
D3.113	
D3.114	
D3.116	

D3.117	
D3.118	
D3.119	
D3.120	

7. Compounds of the general formula D4













wherein







- R11 and R12 represent heterocyclic systems having three to eight ring members, which may be connected to each other directly via the hetero atoms, via carbon atoms or a hetero atom or a carbon atom;
- the partial rings indicated by R1 and R2 may be substituted or unsubstituted, condensed or noncondensed and may contain zero to three double bonds and further hetero atoms and hetero atom-containing groups;
- and tautomers, stereoisomers of the compounds of the general formula D4 and pharmaceutically acceptable salts, salt derivatives, tautomers and stereoisomers thereof, for a use in the medical field.






8. The compounds of the general formula D4 according to claim 7 for a use in the medical field, namely compounds for example, but not exclusively, selected from the following group D4 according to Table 4, and tautomers, stereoisomers of said compounds and pharmaceutically acceptable salts, salt derivatives, tautomers and stereoisomers thereof:

Table 4:






Compound ID.	Structure
D4.001	
D4.002	
D4.003	
D4.004	
D4.005	

D4.006	
D4.007	
D4.008	
D4.009	
D4.010	






D4.011	 <chem>O=C1SCC(=O)N1c2cc(Cl)cc(Cl)c2</chem>
D4.012	 <chem>CN(C)c1nc(C#Nc2ccccc2)c(C#Nc3ccccc3)n1</chem>
D4.013	 <chem>O=C1N2C(=NN1)c3ccccc3N2c4nn[nO]4</chem>
D4.014	 <chem>CC(C)C1CCOC1c2sc3c(s2)nc4c3nc5c4N(C(=O)N6C=CC=C6)C(=O)N7C=CC=C7C(=O)N8C=CC=C8</chem>
D4.015	 <chem>CCOC(=O)c1ccc(cc1)N2C(=O)SCC2=O</chem>
D4.016	 <chem>[O-][N+](=O)c1ccc(cc1)c2c(c(=O)[O-])n(c2)c3ccc(Cl)cc3</chem>

D4.017	
D4.018	
D4.019	
D4.020	
D4.021	













D4.022	
D4.023	
D4.024	
D4.025	
D4.026	








D4.034	 <chem>CN(C)C(=O)N1C(=N2C(=N1)C(=C2)C3=CC=CC=C3)C(=C4C(=C(C=C4)OC)C=C5C=CC=C55)C6=CC=CC=C6</chem>
D4.035	 <chem>O=C1CC(=O)N1c2ccc(cc2[N+](=O)[O-])N(CCN3C=CC=CC=C3)CC4</chem>
D4.036	 <chem>CC(=O)CCc1c2c(c3ccccc3o1)cc([N+](=O)[O-])cc24ccccc44</chem>
D4.037	 <chem>O=C1C(=O)c2cc3c(cc21)nc4ccccc4n3c5cc6c(cc5)nc7c(=O)oc8ccccc8n7C(=O)c9ccccc9</chem>
D4.038	 <chem>CN1C(=N2C(=N1)C(=C2)C(=O)NC(=O)N1C(=O)C(=O)N1)CC3=CC=CC=C3Cl</chem>






D4.039	
D4.040	
D4.041	
D4.042	
D4.044	

D4.045	
D4.046	
D4.047	
D4.048	
D4.049	






D4.050	
D4.051	
D4.052	
D4.053	
D4.054	






D4.055	
D4.056	
D4.057	
D4.058	
D4.059	

P29678.S01






D4.060	 <chem>O=[N+]([O-])c1ccc2c(c1)c3ccccc3c(=O)n2C(=O)c4ccc(cc4)S(=O)(=O)Nc5ccccc5</chem>
D4.061	 <chem>O=[N+]([O-])c1ccc2c(c1)c3ccccc3c(=O)n2C(=O)c4ccc(cc4)S(=O)(=O)Nc5ccccc5</chem>
D4.062	 <chem>O=[N+]([O-])c1ccc2c(c1)c3ccccc3c(=O)n2C(=O)c4ccc(cc4)S(=O)(=O)Nc5ccccc5</chem>
D4.063	 <chem>O=[N+]([O-])c1ccc2c(c1)c3ccccc3c(=O)n2C(=O)c4ccc(cc4)S(=O)(=O)Nc5ccccc5</chem>
D4.064	 <chem>O=[N+]([O-])c1ccc2c(c1)c3ccccc3c(=O)n2C(=O)c4ccc(cc4)S(=O)(=O)Nc5ccccc5</chem>








D4.065	
D4.066	
D4.067	
D4.068	
D4.069	








D4.070	
D4.071	
D4.072	
D4.073	
D4.074	






P29678.S01






D4.075	
D4.076	
D4.077	
D4.078	
D4.079	







D4.080	 <p>Chemical structure of a pyridine derivative. It features a pyridine ring substituted with a 4-bromophenyl group, a cyano group, and an isopropyl group.</p>
D4.081	 <p>Chemical structure of a pyridine derivative. It features a pyridine ring substituted with a 4-chlorophenyl group, a cyano group, and a propyl group.</p>
D4.082	 <p>Chemical structure of a pyridine derivative. It features a pyridine ring substituted with a phenyl group, a cyano group, and a propyl group.</p>
D4.083	 <p>Chemical structure of a pyridine derivative. It features a pyridine ring substituted with a 4-chlorophenyl group, a cyano group, and a propyl group.</p>
D4.084	 <p>Chemical structure of a pyridine derivative. It features a pyridine ring substituted with a phenyl group, a cyano group, and a propyl group.</p>

P29678.S01





D4.085	
D4.086	
D4.087	
D4.088	
D4.089	
D4.090	
D4.091	




D4.092	
D4.093	
D4.095	
D4.096	
D4.098	

D4.099	
D4.100	
D4.101	
D4.102	
D4.103	


D4.104	 <p>Chemical structure of 2-amino-4-cyano-6-methyl-1-phenyl-3-(prop-1-en-1-yl)pyrimidine. The pyrimidine ring is substituted with an amino group (NH<sub>2</sub>) at position 2, a cyano group (C≡N) at position 4, a methyl group (H<sub>3</sub>C) at position 6, a phenyl ring at position 1, and a prop-1-en-1-yl group at position 3.</p>
D4.105	 <p>Chemical structure of 1-(2-oxo-2-phenyl-1H-benzotriazin-4-yl)-2-phenyl-1H-benzotriazin-4-one. The structure features two benzotriazin-4-one moieties linked by a 1,1'-biphenyl group.</p>
D4.106	 <p>Chemical structure of 1-(4-acetoxyphenyl)-2,3-diphenylisoindolin-1-one. The isoindolin-1-one core is substituted with two phenyl groups at positions 2 and 3, and a 4-acetoxyphenyl group at position 1.</p>
D4.107	 <p>Chemical structure of 1-(2-ethoxy-4-methoxyphenyl)-2-phenyl-1H-benzotriazin-4-one. The benzotriazin-4-one core is substituted with a phenyl group at position 2 and a 2-ethoxy-4-methoxyphenyl group at position 1.</p>
D4.110	 <p>Chemical structure of 1-(2-phenyl-1,3,4-oxadiazol-5-yl)-2-phenyl-1H-benzotriazin-4-one. The benzotriazin-4-one core is substituted with a phenyl group at position 2 and a 2-phenyl-1,3,4-oxadiazol-5-yl group at position 1.</p>
D4.111	 <p>Chemical structure of 1-(4-chlorophenyl)-2-(4-(dimethylamino)phenyl)-3-phenyl-1,3,4-oxadiazol-5-yl. The 1,3,4-oxadiazole ring is substituted with a 4-chlorophenyl group at position 1, a 4-(dimethylamino)phenyl group at position 2, and a phenyl group at position 3.</p>



D4.112	
D4.113	
D4.114	
D4.115	

D4.116	
D4.117	
D4.118	

## 9. Compounds of the general formula D5



wherein






- X may represent O, S, NH, NR<sub>2</sub>;
- the residues R1 symbolize the substitution of the basic six-membered ring structure;
- the basic heterocyclic structure may possess zero to three double bonds and up to three further hetero atoms from the group X;






- R1 and R2 are selected from the group consisting of hydrogen, unsubstituted or substituted, straight chain or branched C<sub>1</sub>- to C<sub>12</sub> alkyl, C<sub>2</sub>- to C<sub>12</sub> alkenyl and C<sub>2</sub>- to C<sub>12</sub> alkynyl, hydroxy, thiol, C<sub>1</sub>- to C<sub>12</sub> alkoxy, C<sub>1</sub>- to C<sub>12</sub> alkylthio, unsubstituted or substituted, uncondensed or condensed aryl and cycloalkyl optionally containing one or several hetero atoms from the group N, O, P and S, unsubstituted or substituted amino, unsubstituted or substituted carbonyl, unsubstituted or substituted thiocarbonyl and unsubstituted or substituted imino;
- the heteroaromatic or heterocyclic residues are bound to the basic structure of the general formula D5 via a C atom or a hetero atom;
- and tautomers, stereoisomers of the compounds of the general formula D5 and pharmaceutically acceptable salts, salt derivatives, tautomers and stereoisomers thereof, for a use in the medical field.





10. The compounds of the general formula D5 according to claim 9 for a use in the medical field, namely compounds for example, but not exclusively, selected from the following group D5 according to Table 5, and tautomers, stereoisomers of said compounds and pharmaceutically acceptable salts, salt derivatives, tautomers and stereoisomers thereof:

**Table 5:**






Compound ID.	Structure
D5.001	






D5.002	
D5.003	
D5.004	
D5.005	
D5.006	

D5.007	 <chem>Cc1c(C#N)c2ccccc2n1C3=CC=C(C=C3)OC4=CC=C(C=C4)Cl</chem>
D5.008	 <chem>CC1=CC=C(C=C1)N2C(=O)C(=CN2)SC3CC(OC3C4=CC=CC=C4C)C5=CC=CC=C5C6=CC=C(C=C6)SC7C(=O)N(C8=CC=C(C=C8)C)C8=CC=C(C=C8)C9=CC=CC=C9</chem>
D5.009	 <chem>O=C1NCCOCC1C2=CC=C(C=C2)[N+](=O)[O-]C3=CC=C(C=C3)C4=CC=CC=C4N5CCOCC5C6=CC=C(C=C6)C7=CC=CC=C7C8=CC=CC=C8</chem>
D5.010	 <chem>CCOC(=O)c1ccc(cc1)N2C(=O)CCSC2=O</chem>
D5.011	 <chem>CCOC(=O)c1cc(ccc1N2C(=O)C(=CN2)SC3CC(OC3C4=CC=CC=C4C)C5=CC=CC=C5C6=CC=C(C=C6)SC7C(=O)N(C8=CC=C(C=C8)C)C8=CC=C(C=C8)C9=CC=CC=C9)[N+](=O)[O-]</chem>

D5.013	
D5.014	
D5.015	
D5.016	






P29678.S01





D5.017	
D5.018	
D5.019	
D5.020	
D5.021	

D5.022	 <chem>COC1=CC=C(C=C1C2C(=O)NCC2=O)Cl</chem>
D5.023	 <chem>CCN1C=NC2C(=O)N1C2N3CCCN(C3)CC(=O)c4c[nH]c5ccccc45</chem>
D5.024	 <chem>COC1=CC=C(C=C1CN2CCCC2)C3=CC(OC)=CC(OC)=C3NCC#N</chem>
D5.025	 <chem>Clc1ccc(cc1)CN2C(=O)c3cc(ccc3N2N=C4N5C(=O)N(C)C5=CC(=C4)S(=O)(=O)N6CCOCC6)N(C)C7=CC=C(C=C7)N=C8S(=O)N(C)C8=CC(F)=CC=C8</chem>
D5.026	 <chem>O=C1CCCC(=O)N1c2ccc(cc2N3CCCC3=O)N4CCCC4[N+](=O)[O-]</chem>













P29678.S01

D5.027	
D5.028	
D5.029	
D5.030	
D5.031	






D5.032	 <chem>CC(C)c1ccc2c(c1)c(c[nH]2)C3=CC=CC=C3C(=O)O</chem>
D5.033	 <chem>CC(C)c1ccc2c(c1)c(c[nH]2)C3=CC=CC=C3C(=O)O</chem>
D5.034	 <chem>CC(C)c1ccc2c(c1)c(c[nH]2)C3=CC=CC=C3C(=O)O</chem>
D5.035	 <chem>CC(C)c1ccc2c(c1)c(c[nH]2)C3=CC=CC=C3C(=O)O</chem>



P29678.S01

D5.036	
D5.037	
D5.038	
D5.039	
D5.040	


D5.041	
D5.042	
D5.043	
D5.044	
D5.045	

P29678.S01

D5.046	
D5.047	
D5.048	
D5.050	
D5.051	

D5.052	
D5.053	

## 11. Compounds of the general formula D6



wherein

- X may represent O, S, NH or NR<sup>9</sup>;
- the basic five-membered ring structure may additionally contain up to three further hetero atoms in accordance with the definition of X, which may be identical or different;
- the basic five-membered ring structure may contain zero to two double bonds;
- R<sup>1</sup> to R<sup>9</sup> are selected from the group consisting of hydrogen, unsubstituted or substituted, straight chain or branched C<sub>1</sub>- to C<sub>12</sub> alkyl, C<sub>2</sub>- to C<sub>12</sub> alkenyl and C<sub>2</sub>- to C<sub>12</sub> alkynyl, hydroxy, thiol, C<sub>1</sub>- to C<sub>12</sub> alkoxy, C<sub>1</sub>- to C<sub>12</sub> alkylthio, unsubstituted or substituted, uncondensed or condensed aryl and cycloalkyl optionally containing one or several hetero atoms from the group N, O, P and S, un-


substituted or substituted amino, unsubstituted or substituted carbonyl, unsubstituted or substituted thiocarbonyl and unsubstituted or substituted imino; and






- the heteroaromatic or heterocyclic residues are bound to the basic structure of the general formula D6 via a C atom or a hetero atom;

and tautomers, stereoisomers of the compounds of the general formula D6 and pharmaceutically acceptable salts, salt derivatives, tautomers and stereoisomers thereof, for a use in the medical field.

12. The compounds of the general formula D6 according to claim 11 for a use in the medical field, namely compounds for example, but not exclusively, selected from the following group D6 according to Table 6, and tautomers, stereoisomers of said compounds and pharmaceutically acceptable salts, salt derivatives, tautomers and stereoisomers thereof:






**Table 6:**

Compound ID.	Structure
D6.001	







D6.002	
D6.003	
D6.004	
D6.006	
D6.007	















D6.012	 <chem>CC1=CC=C(C=C1)N2C(=O)N3C(=N2)SC(C)C(=O)N4CCOCC4C5C=C3SC6C=C(C=C(COCC6C5)C)C</chem>
D6.013	 <chem>c1ccc2c(c1)c3nc4c(ncn4c3)C(=O)N=Nc5c6ccccc6c7ccccc57</chem>
D6.014	 <chem>[O-][N+](=O)c1ccc(cc1)C2=C(C(=O)N2c3ccc(Cl)cc3)C4=CC=CC=C4</chem>
D6.015	 <chem>CCOc1cc(=O)ccc1C=NNC(=O)c2cc3nn[nH]3c2</chem>
D6.016	 <chem>Cc1ccsc1C(=O)N=C(N)OC(=O)c2cc(Br)oc2</chem>







P29678.S01






D6.017	
D6.018	
D6.019	
D6.020	
D6.021	
D6.022	







D6.023	 <chem>O=[N+]([O-])c1ccc(cc1)/C=N2C(=O)N(C(=O)N2/C=N/C3=CC=C(C=C3)OC4=CC=C(C=C4)Cl)C5=CC=CC=C5</chem>
D6.024	 <chem>O=C(NC(=O)c1ccccc1)C(=C2C=CC=C2S)NNC3=CC(=CC(=C3)[N+](=O)[O-])C(=O)OC4=CC=CC=C4O</chem>
D6.025	 <chem>O=C(NC(=O)c1ccccc1)C(=C2C=CC=C2S)NNC3=CC(=CC(=C3)[N+](=O)[O-])[N+](=O)[O-]</chem>
D6.026	 <chem>CCOC(=O)n1cc(C(=O)Nc2ccccc2F)nn1</chem>
D6.027	 <chem>CC1CCN(C1)C(=O)C(=C2C=CC=C2O)C(=O)N3C(=O)C(=CC=C3Cl)C4=CC=CC=C4</chem>

D6.028	
D6.029	
D6.030	
D6.031	
D6.032	

P29678.S01







D6.033	
D6.034	
D6.035	
D6.036	
D6.037	
D6.038	






D6.039	 <chem>O=C(NC(=C1C=CC=C1S)C(=O)NN=C2C=CC(=C2)C(=O)OC3=CC=CO3)C4=CC=CC=C4Br</chem>
D6.040	 <chem>COc1ccc(cc1)/C=N2N=C(C(=N2)C3=CC=CC=C3)C(=C4C=CC=CC4)C(=O)N(C)C</chem>
D6.041	 <chem>CC(=O)CCCc1c2ccccc2oc1-c1cc(C)ccoc1[N+](=O)[O-]</chem>
D6.042	 <chem>Nc1ccc2c(c1)C(=O)C=Cc3ccoc3O2</chem>
D6.043	 <chem>CN1C=NC2=C1C(=O)N(C)C(=O)N2C3=CC=CC=C3Cl</chem>

D6.044	 <chem>CC1=Cc2ccccc2N1CCNC(=O)c3ccsc3</chem>
D6.045	 <chem>CC1=CN=C(C1)C(=O)NN=C(C)C2=CC=C(C=C2)C3=CC=CC=C3</chem>
D6.046	 <chem>CCN1C=NC2=C1C(=O)N(C)C2=OCCN3CCN(CC3)CC(=O)c4c[nH]c5ccccc45</chem>
D6.047	 <chem>CC(=O)Nc1c[nH]c2ccccc12</chem>
D6.048	 <chem>CC1=CN=C(C1)C(=O)NN=C(C)C2=CC=C(C=C2)C3=CC=CC=C3</chem>
D6.049	 <chem>CC1=CN=C(C1)C(=O)NN=C(C)C2=CC=C(C=C2)C3=CC=CC=C3</chem>







P29678.S01







D6.050	
D6.051	
D6.052	
D6.053	
D6.054	
D6.055	






D6.056	 <chem>COCCOC(=O)c1c(C)nn(c1Nc2ccc(cc2)N3C(=O)CCSC3=O)C</chem>
D6.057	 <chem>Cc1ccc(cc1)NC(=O)CS2C=CN2</chem>
D6.058	 <chem>FC(F)(F)C(=O)Nc1sc2c(c1)C#Nc3ccccc23</chem>
D6.059	 <chem>O=[N+]([O-])c1ccc(cc1)C2=NC3=C(N2Cc4ccc(F)cc4)SC5=CC=CC=C5C6=CC=CC=C6C(=O)N7C(=O)C8=CC=CC=C8C7=O6</chem>
D6.060	 <chem>CN1CCN(C1)C2=NC3=C(N2Cc4cc(F)ccc4)C(=O)N(C)C(=O)N3C(=O)C5=CC=CC=C5</chem>







P29678.S01





D6.061	
D6.062	
D6.063	
D6.064	








D6.070	
D6.071	
D6.072	
D6.073	
D6.074	
D6.075	

D6.076	
D6.077	
D6.078	
D6.079	
D6.080	







D6.081	
D6.082	
D6.083	
D6.084	
D6.085	
D6.086	

D6.087	
D6.088	
D6.089	
D6.090	













D6.091	
D6.092	
D6.094	
D6.095	
D6.096	






P29678.S01







D6.097	
D6.098	
D6.099	
D6.100	
D6.101	
D6.102	






P29678.S01





D6.103	
D6.105	
D6.106	
D6.107	
D6.108	

D6.110	
D6.111	
D6.112	
D6.113	
D6.114	

D6.115	
D6.116	
D6.117	
D6.118	
D6.119	


D6.120	
D6.121	
D6.122	
D6.123	
D6.124	
D6.125	

D6.126	
D6.127	
D6.129	
D6.130	
D6.131	

D6.132	 <p>Chemical structure of 4-(4-amino-1,3,4-thiazol-2-yl)benzenesulfonyl-2-amino-1,3,4-thiazole. It consists of two 1,3,4-thiazole rings connected by a sulfonyl group (-SO<sub>2</sub>-) at their 2-positions. Each thiazole ring has an amino group (-NH<sub>2</sub>) at the 4-position.</p>
D6.133	 <p>Chemical structure of 1-(4-((4-ethoxyphenyl)diazenyl)furan-2-yl)-4-((4-ethoxyphenyl)diazenyl)-5-nitro-2-phenyl-1H-benzotriazole. It features a central benzotriazole core substituted with a phenyl group at position 2, a 4-ethoxyphenyl group at position 4, and a 5-nitro-2-phenyl group at position 5. The benzotriazole ring is also substituted with a 4-ethoxyphenyl group at position 1.</p>
D6.134	 <p>Chemical structure of 1-(4-((4-ethoxyphenyl)diazenyl)furan-2-yl)-4-((4-ethoxyphenyl)diazenyl)-5-nitro-2-phenyl-1H-benzotriazole. It features a central benzotriazole core substituted with a phenyl group at position 2, a 4-ethoxyphenyl group at position 4, and a 5-nitro-2-phenyl group at position 5. The benzotriazole ring is also substituted with a 4-ethoxyphenyl group at position 1.</p>
D6.135	 <p>Chemical structure of 1-(4-((4-ethoxyphenyl)diazenyl)furan-2-yl)-4-((4-ethoxyphenyl)diazenyl)-5-nitro-2-phenyl-1H-benzotriazole. It features a central benzotriazole core substituted with a phenyl group at position 2, a 4-ethoxyphenyl group at position 4, and a 5-nitro-2-phenyl group at position 5. The benzotriazole ring is also substituted with a 4-ethoxyphenyl group at position 1.</p>



## 13. Compounds of the general formulae D7





wherein

- Y1 and Y2 may be identical or different and may represent O, S, NH or NR<sub>4</sub>;
- the aromatic systems of the basic structures may contain up to four substituents, which may be identical or different;
- R1 to R4 are selected from the group consisting of hydrogen, unsubstituted or substituted, straight chain or branched C<sub>1</sub>- to C<sub>12</sub> alkyl, C<sub>2</sub>- to C<sub>12</sub> alkenyl and C<sub>2</sub>- to C<sub>12</sub> alkynyl, hydroxy, thiol, C<sub>1</sub>- to C<sub>12</sub> alkoxy, C<sub>1</sub>- to C<sub>12</sub> alkylthio, unsubstituted or substituted, uncondensed or condensed aryl and cycloalkyl optionally containing one or several hetero atoms from the group N, O, P and S, unsubstituted or substituted amino, unsubstituted or substituted carbonyl, unsubstituted or substituted thiocarbonyl and unsubstituted or substituted imino; and
- the heteroaromatic or heterocyclic residues are bound to the basic structure having the general formula D7 via a C atom or a hetero atom;
- R2 and R3 symbolize the substitution of the respective rings systems and represent one to four residues;
- and tautomers, stereoisomers of the compounds of the general formula D6 and pharmaceutically acceptable salts, salt derivatives, tautomers and stereoisomers thereof, for a use in the medical field.


P29678.S01

14. The compounds of the general formula D7 according to claim 13 for a use in the medical field, namely compounds for example, but not exclusively, selected from the following group D7 according to Table 7, and tautomers, stereoisomers of said compounds and pharmaceutically acceptable salts, salt derivatives, tautomers and stereoisomers thereof:

**Table 7:**

Compound ID.	Structure
D7.001	
D7.003	

15. Compounds of the general formula D8



wherein

- X and Z may be identical or different and independent of each other are selected from the group consisting of hydroxy, thiol, C<sub>1</sub>- to C<sub>12</sub> alkoxy, C<sub>1</sub>- to C<sub>12</sub>

alkylthio, unsubstituted or substituted, uncondensed or condensed aryl and cycloalkyl optionally containing one or several hetero atoms from the group N, O, P and S and amino (NH<sub>2</sub>, NHR<sub>1</sub>, NR<sub>1</sub>R<sub>2</sub>);





- Y represents O, S or NR<sub>3</sub>;
- R<sub>1</sub>, R<sub>2</sub> and R<sub>3</sub> may be identical or different and are selected from the group consisting of hydrogen, unsubstituted or substituted, straight chain or branched C<sub>1</sub>- to C<sub>12</sub> alkyl, C<sub>2</sub>- to C<sub>12</sub> alkenyl and C<sub>2</sub>- to C<sub>12</sub> alkynyl, hydroxy, thiol, C<sub>1</sub>- to C<sub>12</sub> alkoxy, C<sub>1</sub>- to C<sub>12</sub> alkylthio, unsubstituted or substituted, uncondensed or condensed aryl and cycloalkyl optionally containing one or several hetero atoms from the group N, O, P and S, unsubstituted or substituted amino, unsubstituted or substituted carbonyl, unsubstituted or substituted thiocarbonyl and unsubstituted or substituted imino; and
- the heteroaromatic or heterocyclic residues are bound to the basic structure having the general formula D8 via a C atom or a hetero atom;

and tautomers, stereoisomers of the compounds of the general formula D8 and pharmaceutically acceptable salts, salt derivatives, tautomers and stereoisomers thereof, for a use in the medical field.






16. The compounds of the general formula D8 according to claim 15 for a use in the medical field, namely compounds for example, but not exclusively, selected from the following group D8 according to Table 8, and tautomers, stereoisomers of said compounds and pharmaceutically acceptable salts, salt derivatives, tautomers and stereoisomers thereof:





P29678.S01

**Table 8:**






Compound ID.	Structure
D8.001	
D8.002	
D8.003	
D8.004	






P29678.S01

D8.005	 <chem>BrC1=CC=C(C=C1)/C=N/N=C2C3=CC=CC=C3N=C2</chem>
D8.006	 <chem>CC1=CC=C2C(=C1)N(C)C(=C2)C(=O)NCCN3CCCN(C3)C4=NC5=C(N(C)C5=O)N=CN4</chem>
D8.007	 <chem>COCCN(C1=CC=C(C=C1)C=C1C=CN2C(=O)N(C)C(=O)N2C1)CCN3CCCN(C3)C4=NC5=C(N(C)C5=O)N=CN4</chem>
D8.008	 <chem>CCOC(=O)N1C=CC=C1C(=O)N2C(=CC=C2)C(=O)N2C3=CC=CC=C3F</chem>
D8.009	 <chem>O=C(C(=O)N1C=CC=C1)C(S2C3=NC=CC=N3S2)C4=CC=CC=C4</chem>





D8.010	 <chem>CN1C=NC2=C1N(CCN2Cc3ccccc3)C(=O)N1C=NC(=C1)C(=O)N</chem>
D8.011	 <chem>CC(C)C1=CC=C2C(=C1)OC(=CC=C2S2)N(CCN2C(=O)N(CCN2)Cc3ccccc3)SCC(=O)C(=O)O</chem>
D8.012	 <chem>CC(=O)Oc1ccc(cc1)C(=O)Nc2ccc(cc2)OCC(=O)O</chem>
D8.013	 <chem>CN1C=NC2=C1N(CCN2Cc3ccccc3Cl)C(=O)N1C=NC(=C1)C(=O)N</chem>






P29678.S01






D8.014	
D8.015	
D8.016	
D8.017	
D8.018	

D8.019	 <chem>O=C1N=C(S1)CCc2c[nH]c3ccccc23</chem>
D8.020	 <chem>CN1CCN(C)CC1C2=CN3C(=O)N(C)C(=O)N3C(=O)C2Cc4ccc(F)cc4</chem>
D8.021	 <chem>O=C1N2C(=O)N3C(=N1)C4=CC=CC=C4N2C3c5ccccc5</chem>
D8.022	 <chem>CN1C(=O)N(C)C(=O)C2=C1N(CCN2Cc3cc(Cl)ccc3)N3CCO3</chem>
D8.023	 <chem>NC1=NC(=N1)N=NC(=O)OC(=O)OC</chem>




D8.024	 <chem>CN1C=NC2=C1C(=O)SC(=S)N2C</chem>
D8.025	 <chem>CCOP(=O)(OCC)CCN1C(=O)N(Cc2ccc(N)cc2)C(=O)N1C(=O)Nc3ccc(Br)cc3</chem>
D8.026	 <chem>CN1CCN(C1)c2nc3c(nc(=O)n3C(=O)NCCc4ccccc4)nc(C)n2Cc5ccccc5</chem>
D8.027	 <chem>Cc1ccc(cc1)CN2C=CC=C2N=NC(=S)Nc3cc(C)cc(C)c3</chem>

D8.028	 <chem>CCOC(=O)c1nc2ccc(F)cc2n1C(=O)NCC(=O)N3CCN(C4C(=O)N(C)C(=O)N4CC)CC3</chem>
D8.029	 <chem>CCOC(=O)N1CCN(C2=CC(=CC=C2)[N+](=O)[O-])CC1N3C(=O)CC(=O)N3</chem>
D8.030	 <chem>CC1=CC=C(C=C1)CC2C(=O)N(C)C(=O)N2C(=O)NCC(O)CO</chem>
D8.031	 <chem>CC1=CC=C(C=C1)N(C)C(=O)O[N+]1=CC=C(C)C=C1OC</chem>
D8.032	 <chem>CCOC(=O)ON=C(N)C(=N)N=OCC(=O)OCC</chem>

D8.033	 <chem>CC1=CC=C(C=C1)C(=O)N(C1(Cl)C(Cl)C1)N(C2=CC3=C(C(=C2)C(=O)N)SC3)C=S</chem>
D8.034	 <chem>CC(C)Oc1ccc(cc1)CSc2nc3nc4c(nc3n2)SCC5=C4SCC6C(C)(C)OCC56</chem>
D8.035	 <chem>CN(C)c1ccc[n+](c1)C(=O)N(C)C</chem>
D8.037	 <chem>c1ccc(cc1)C(=O)N2C(=O)c3cc4c(c2s3)nnn4C(=O)c5ccccc5</chem>
D8.038	 <chem>O=[N+]([O-])c1nn[n+](c1)/C=C/c2cc3cc(Cl)c(Cl)cc3o2</chem>

17. Compounds of the general formulae D9



wherein

- Z may represent S or P;
- Y1 and Y2 may represent O, S, NH, NR<sub>4</sub> or NR<sub>5</sub>;
- R1 to R5 are selected from the group consisting of hydrogen, unsubstituted or substituted, straight chain or branched C<sub>1</sub>- to C<sub>12</sub> alkyl, C<sub>2</sub>- to C<sub>12</sub> alkenyl and C<sub>2</sub>- to C<sub>12</sub> alkynyl, hydroxy, thiol, C<sub>1</sub>- to C<sub>12</sub> alkoxy, C<sub>1</sub>- to C<sub>12</sub> alkylthio, unsubstituted or substituted, uncondensed or condensed aryl and cycloalkyl optionally containing one or several hetero atoms from the group N, O, P and S, unsubstituted or substituted amino, unsubstituted or substituted carbonyl, unsubstituted or substituted thiocarbonyl and unsubstituted or substituted imino;
- the heteroaromatic or heterocyclic residues are bound to the basic structure having the general formula D9 via a C atom or a hetero atom;






and tautomers, stereoisomers of the compounds of the general formula D9 and pharmaceutically acceptable salts, salt derivatives, tautomers and stereoisomers thereof, for a use in the medical field.

18. The compounds of the general formula D9 according to claim 17 for a use in the medical field, namely compounds for example, but not exclusively, selected from the following group D9 according to Table 9, and tautomers, stereoisomers of






P29678.S01





said compounds and pharmaceutically acceptable salts, salt derivatives, tautomers and stereoisomers thereof:

**Table 9:**


Compound ID.	Structure
D9.001	
D9.002	
D9.003	
D9.004	
D9.005	

P29678.S01

D9.006	
D9.007	
D9.008	
D9.010	
D9.011	

D9.012	 <p>Chemical structure of 4-(4-amino-1,3,4-thiadiazol-2-yl)benzenesulfonyl-2-amino-1,3,4-thiadiazole. It consists of two 1,3,4-thiadiazole rings connected by a sulfonyl group (-SO<sub>2</sub>-). One ring has an amino group (-NH<sub>2</sub>) at the 2-position, and the other has an amino group at the 4-position.</p>
D9.013	 <p>Chemical structure of a complex molecule. It features a central sulfonamide group (-SO<sub>2</sub>-NH-) connected to a phenyl ring with a chlorine atom and a methoxy group. The sulfonamide is also connected to a hydrazide group (-NH-CO-NH-) which is further connected to a phenyl ring with a methoxy group. The hydrazide is also connected to a phenyl ring with a chlorine atom and a methoxy group.</p>
D9.014	 <p>Chemical structure of a complex molecule. It features a central sulfonamide group (-SO<sub>2</sub>-NH-) connected to a phenyl ring with a chlorine atom and a methoxy group. The sulfonamide is also connected to a hydrazide group (-NH-CO-NH-) which is further connected to a phenyl ring with a methoxy group. The hydrazide is also connected to a phenyl ring with a chlorine atom and a methoxy group.</p>
D9.015	 <p>Chemical structure of a complex molecule. It features a central sulfonamide group (-SO<sub>2</sub>-NH-) connected to a phenyl ring with a chlorine atom and a methoxy group. The sulfonamide is also connected to a hydrazide group (-NH-CO-NH-) which is further connected to a phenyl ring with a methoxy group. The hydrazide is also connected to a phenyl ring with a chlorine atom and a methoxy group.</p>

19. Compounds of the general formula D10



wherein





- R1, R2, R3 and R4 are selected from the group consisting of hydrogen, unsubstituted or substituted, straight chain or branched C<sub>1</sub>- to C<sub>12</sub> alkyl, C<sub>2</sub>- to C<sub>12</sub> alkenyl and C<sub>2</sub>- to C<sub>12</sub> alkynyl, hydroxy, thiol, C<sub>1</sub>- to C<sub>12</sub> alkoxy, C<sub>1</sub>- to C<sub>12</sub> alkylthio, unsubstituted or substituted, uncondensed or condensed aryl and cycloalkyl optionally containing one or several hetero atoms from the group N, O, P and S, unsubstituted or substituted amino, unsubstituted or substituted carbonyl, unsubstituted or substituted thiocarbonyl and unsubstituted or substituted imino;
- the heteroaromatic or heterocyclic residues are bound to the basic structure having the general formula D10 via a C atom or a hetero atom;






and tautomers, stereoisomers of the compounds of the general formula D10 and pharmaceutically acceptable salts, salt derivatives, tautomers and stereoisomers thereof, for a use in the medical field.







20. The compounds of the general formula D10 according to claim 19 for a use in the medical field, namely compounds for example, but not exclusively, selected from the following group D10 according to Table 10, and tautomers, stereoisomers of said compounds and pharmaceutically acceptable salts, salt derivatives, tautomers and stereoisomers thereof:














Table 10:

Compound ID.	Structure
D10.001	
D10.002	
D10.003	
D10.004	







D10.005	
D10.007	
D10.008	
D10.009	
D10.010	







D10.011	
D10.012	
D10.013	
D10.014	
D10.015	
D10.016	







D10.017	
D10.018	
D10.019	
D10.020	
D10.021	
D10.022	

D10.023	
D10.025	
D10.026	
D10.027	
D10.028	







P29678.S01







D10.029	 <chem>O=[N+]([O-])c1cc(cc(c1[N+](=O)[O-])=C/N=N/C(=O)Nc2ccccc2)C3=CC=CC=C3S</chem>
D10.030	 <chem>O=[N+]([O-])c1cc(cc(c1[N+](=O)[O-])=C/N=N/C(=O)Oc2ccc(C)cc2</chem>
D10.031	 <chem>COC1=CC=CC2=C1C(=O)N=N/C(=O)Nc3ccc4ccccc4c3=O</chem>
D10.032	 <chem>O=[N+]([O-])c1ccc2c(c1)c3ccccc3n2C(=O)N=N/C(=O)Nc4ccc5ccccc5c4</chem>
D10.033	 <chem>O=[N+]([O-])c1cc(cc(c1[N+](=O)[O-])=C/N=N/C(=O)Oc2ccc(C(C)(C)C)cc2</chem>
D10.034	 <chem>CCOc1cc(cc(c1Cl)Cl)C(=O)N=N/C(=O)c2cc(Cl)c(Cl)c(Cl)c2</chem>







D10.035	
D10.036	
D10.037	
D10.038	
D10.039	
D10.040	







D10.041	
D10.042	
D10.043	
D10.044	
D10.045	
D10.046	









D10.047	
D10.049	
D10.050	
D10.051	
D10.052	
D10.053	

D10.054	
D10.055	
D10.056	
D10.057	
D10.058	
D10.060	







D10.061	
D10.062	
D10.063	
D10.065	
D10.066	
D10.067	







D10.068	
D10.069	
D10.070	
D10.071	
D10.072	
D10.073	

D10.074	
D10.075	
D10.076	
D10.077	
D10.078	







D10.079	
D10.081	
D10.082	
D10.083	
D10.084	
D10.085	







P29678.S01






D10.086	
D10.087	
D10.088	
D10.089	
D10.090	
D10.091	







D10.092	
D10.093	
D10.094	
D10.095	
D10.097	
D10.098	














D10.099	
D10.100	
D10.101	
D10.102	
D10.103	
D10.105	







D10.106	
D10.107	
D10.108	
D10.109	
D10.110	
D10.111	


D10.113	
D10.116	
D10.117	
D10.118	
D10.119	

D10.120	
D10.121	
D10.122	
D10.123	
D10.124	
D10.125	


D10.126	 <chem>c1ccccc1CNc2ccc(cc2)C(=O)N=N/C=C/c3cc(ccc3[N+](=O)[O-])</chem>
D10.128	 <chem>COc1cc(OC)c(OC)cc1C/N=N/C(=O)c2ccccc2[N+](=O)[O-]</chem>
D10.129	 <chem>COC(=O)c1ccc(cc1)/N=N/C(=O)c2nn(C3C4C5C6C7C8C9C4C5C6C7C8C9)cc23</chem>
D10.130	 <chem>O=C1C=CC(=N1)c2ccc3ccccc3c2C(=O)N=N/C=C/c4cc(=O)ccc4</chem>
D10.131	 <chem>COc1ccc(cc1)COC(=O)N=N/C=C/c2cc(OC(=O)c3ccc(cc3)[N+](=O)[O-])cc2</chem>

D10.132	
D10.133	
D10.134	
D10.135	
D10.136	
D10.137	

D10.138	
D10.139	
D10.140	
D10.141	
D10.142	
D10.143	



21. Compounds of the general formula D11



wherein

- R1, R2 and R3 are selected from the group consisting of hydrogen, unsubstituted or substituted, straight chain or branched C<sub>1</sub>- to C<sub>12</sub> alkyl, C<sub>2</sub>- to C<sub>12</sub> alkenyl and C<sub>2</sub>- to C<sub>12</sub> alkynyl, hydroxy, thiol, C<sub>1</sub>- to C<sub>12</sub> alkoxy, C<sub>1</sub>- to C<sub>12</sub> alkylthio, unsubstituted or substituted, uncondensed or condensed aryl and cycloalkyl optionally containing one or several hetero atoms from the group N, O, P and S, unsubstituted or substituted amino, unsubstituted or substituted carbonyl, unsubstituted or substituted thiocarbonyl and unsubstituted or substituted imino;
- the heteroaromatic or heterocyclic residues are bound to the basic structure having the general formula D11 via a C atom or a hetero atom;

and tautomers, stereoisomers of the compounds of the general formula D11 and pharmaceutically acceptable salts, salt derivatives, tautomers and stereoisomers thereof, for a use in the medical field.



22. The compounds of the general formula D11 according to claim 21 for a use in the medical field, namely compounds for example, but not exclusively, selected from the following group D11 according to Table 11, and tautomers, stereoisomers











P29678.S01

of said compounds and pharmaceutically acceptable salts, salt derivatives, tautomers and stereoisomers thereof:


**Table 11:**

Compound ID.	Structure
D11.001	 <p>The chemical structure of compound D11.001 consists of a furan-2-ylmethylidene group connected via a methylene bridge to a 4-((2-chlorophenyl)diazenyl)phenyl group. The furan ring is attached to the methylene group at the 2-position. The phenyl ring is attached to the methylene group at the 4-position. The diazenyl group is attached to the phenyl ring at the 2-position, and the chlorine atom is attached to the phenyl ring at the 3-position.</p>
D11.002	 <p>The chemical structure of compound D11.002 consists of a furan-2-ylmethylidene group connected via a methylene bridge to a 4-((2,6-diiodo-3-oxophenyl)diazenyl)phenyl group. The furan ring is attached to the methylene group at the 2-position. The phenyl ring is attached to the methylene group at the 4-position. The diazenyl group is attached to the phenyl ring at the 2-position, and the 2,6-diiodo-3-oxophenyl group is attached to the diazenyl group at the 1-position.</p>

D11.003	
D11.004	
D11.006	
D11.007	
D11.008	

D11.009	
D11.010	
D11.011	

## 23. Compounds of the general formula D12



wherein

- X and Z may be identically or different and independent of each other are selected from the group consisting of hydroxy, thiol, C<sub>1</sub>- to C<sub>12</sub> alkoxy, C<sub>1</sub>- bis C<sub>12</sub>-Alkylthio, unsubstituted or substituted, uncondensed or condensed aryl and cycloalkyl optionally containing one or several heteroatome from the group N, O, P and S and amino (NH<sub>2</sub>, NHR<sub>2</sub>, NR<sub>2</sub>R<sub>3</sub>);
- Y represents O, S or NR<sub>4</sub>;
- R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub> and R<sub>4</sub> may be identical or different and are selected from the group consisting of hydrogen, unsubstituted or substituted, straight chain or


branched C<sub>1</sub>- to C<sub>12</sub> alkyl, C<sub>2</sub>- to C<sub>12</sub> alkenyl and C<sub>2</sub>- to C<sub>12</sub> alkynyl, hydr-oxy, thiol, C<sub>1</sub>- to C<sub>12</sub> alkoxy, C<sub>1</sub>- to C<sub>12</sub>-Alkylthio unsubstituted or substituted, uncondensed or condensed aryl and cycloalkyl optionally one or several hetero atoms from the group N, O, P and S, unsubstituted or substituted amino, unsubstituted or substituted carbonyl, unsubstituted or substituted thiocarbonyl and unsubstituted or substituted imino;






- the heteroaromatic or heterocyclic residues are bound to the basic structure having the general formula D12 via a C atom or a hetero atom;






and tautomers, stereoisomers of the compounds of the general formula D12 and pharmaceutically acceptable salts, salt derivatives, tautomers and stereoisomers thereof, for a use in the medical field.






24. The compounds of the general formula D12 according to claim 23 for a use in the medical field, namely compounds for example, but not exclusively, selected from the following group D12 according to Table 12, and tautomers, stereoisomers of said compounds and pharmaceutically acceptable salts, salt derivatives, tautomers and stereoisomers thereof:







**Table 12:**

Compound ID.	Structure
D12.001	







D12.002	
D12.003	
D12.004	
D12.006	
D12.009	

D12.010	 <p>Chemical structure of a complex molecule. It features a benzoyl group (C6H5-CO-) attached to a diazo group (-N=N-). The diazo group is connected to a furan ring (5-membered oxygen-containing ring). The furan ring is further connected to a benzoyl group (C6H5-CO-) which is substituted with a nitro group (-NO2).</p>
D12.012	 <p>Chemical structure of a molecule. It features a pyrazole ring (5-membered nitrogen-containing ring) substituted with a piperidine ring (6-membered nitrogen-containing ring). The piperidine ring is further connected to an indole ring (fused benzene and pyrrole rings).</p>
D12.013	 <p>Chemical structure of a molecule. It features a benzoyl group (C6H5-CO-) attached to a diazo group (-N=N-). The diazo group is connected to a benzoyl group (C6H5-CO-) which is substituted with a fluorine atom (-F).</p>
D12.014	 <p>Chemical structure of a molecule. It features a benzoyl group (C6H5-CO-) attached to a diazo group (-N=N-). The diazo group is connected to a pyridine ring (6-membered nitrogen-containing aromatic ring). The pyridine ring is further connected to a benzoyl group (C6H5-CO-).</p>
D12.016	 <p>Chemical structure of a molecule. It features a pyrazole ring (5-membered nitrogen-containing ring) substituted with a benzoyl group (C6H5-CO-). The benzoyl group is further connected to a benzophenone group (C6H5-CO-C6H5).</p>


D12.017	
D12.019	
D12.024	
D12.025	
D12.027	

D12.029	
D12.031	
D12.032	
D12.033	
D12.034	
D12.038	



D12.040	
D12.042	
D12.043	
D12.045	
D12.047	
D12.050	

25. Compounds of the general formula D13






wherein





- X and Z may be identical or different and independent of each other are selected from the group consisting of hydroxy, thiol, C<sub>1</sub>- to C<sub>12</sub> alkoxy, C<sub>1</sub>- C<sub>12</sub> alkylthio, unsubstituted or substituted, uncondensed or condensed aryl and cycloalkyl optionally containing one or several hetero atoms from the group N, O, P and S and amino (NH<sub>2</sub>, NHR<sub>2</sub>, NR<sub>2</sub>R<sub>3</sub>);
- Y represents O, S or NR<sub>5</sub>;
- the aromatic system may be a six-membered ring including a homo- or hetero aromatic system having one to four N atoms in the ring;
- R<sub>1</sub> symbolizes the substitution of the aromatic core of the basic structure and may represent up to five substituents;
- R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub> and R<sub>4</sub> may be identical or different and are selected from the group consisting of hydrogen, unsubstituted or substituted, straight chain or branched C<sub>1</sub>- to C<sub>12</sub> alkyl, C<sub>2</sub>- to C<sub>12</sub> alkenyl and C<sub>2</sub>- to C<sub>12</sub> alkynyl, hydr-oxy, thiol, C<sub>1</sub>- to C<sub>12</sub> alkoxy, C<sub>1</sub>- to C<sub>12</sub> alkylthio, unsubstituted or substituted, uncondensed or condensed aryl and cycloalkyl optionally containing one or several hetero atoms from the group N, O, P and S, unsubstituted or substituted amino, unsubstituted or substituted carbonyl, unsubstituted or substituted thiocarbonyl and unsubstituted or substituted imino;
- the heteroaromatic or heterocyclic residues are bound to the basic structure having the general formula D13 via a C atom or a hetero atom;

and tautomers, stereoisomers of the compounds of the general formula D13 and pharmaceutically acceptable salts, salt derivatives, tautomers and stereo-isomers thereof, for a use in the medical field.


26. The compounds of the general formula D13 according to claim 25 for a use in the medical field, namely compounds for example, but not exclusively, selected from the following group D13 according to Table 13, and tautomers, stereoisomers of said compounds and pharmaceutically acceptable salts, salt derivatives, tautomers and stereoisomers thereof:

**Table 13:**

Compound ID.	Structure
D13.001	
D13.002	
D13.003	

D13.004	 <chem>CCOC(=O)c1c2ccccc2n1C(=O)NCCN3CCN(C4C(=O)N(C)C(=O)N4)CC3</chem>
D13.005	 <chem>CCOC(=O)CC(N)c1ccccc1Cl</chem>
D13.006	 <chem>CCOC(=O)CC(N)c1ccc(OC)cc1</chem>
D13.007	 <chem>CN(C)c1ccc(cc1)C2C(=O)N(c3ccccc3)C(=O)O2N4C(=O)C(=O)N4c5ccc(Cl)cc5</chem>

## 27. Compounds of the general formulae D14



wherein






- Y represents O, S or NR<sub>5</sub>;
- R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub> and R<sub>4</sub> may be identical or different and are selected from the group consisting of hydrogen, unsubstituted or substituted, straight chain or branched C<sub>1</sub>- to C<sub>12</sub> alkyl, C<sub>2</sub>- to C<sub>12</sub> alkenyl and C<sub>2</sub>- to C<sub>12</sub> alkynyl, hydr-oxy, thiol, C<sub>1</sub>- to C<sub>12</sub> alkoxy, C<sub>1</sub>- to C<sub>12</sub> alkylthio, unsubstituted or substituted, uncondensed or condensed aryl and cycloalkyl optionally containing one or several hetero atoms from the group N, O, P and S, unsubstituted or substituted amino, unsubstituted or substituted carbonyl, unsubstituted or substituted thiocarbonyl and unsubstituted or substituted imino; and
- the heteroaromatic or heterocyclic residues are bound to the basic structure having the general formula D14 via a C atom or a hetero atom;



and tautomers, stereoisomers of the compounds of the general formula D14 and pharmaceutically acceptable salts, salt derivatives, tautomers and stereo-isomers thereof, for a use in the medical field.

28. The compounds of the general formula D14 according to claim 27 for a use in the medical field, namely compounds for example, but not exclusively, selected from the following group D14 according to Table 14, and tautomers, stereoisomers

of said compounds and pharmaceutically acceptable salts, salt derivatives, tautomers and stereoisomers thereof:

**Table 14:**

Compound ID.	Structure
D14.001	
D14.002	
D14.003	
D14.004	
D14.005	

D14.006	
D14.007	

29. A pharmaceutical composition, comprising at least one compound of any of the preceding claims 1 to 28, optionally in combination with usual carriers and/or adjuvants.
30. A cosmetic composition, comprising at least one compound of any of the preceding claims 1 to 28, optionally in combination with usual carriers and/or adjuvants.
31. Use of at least one compound or of a pharmaceutical or cosmetic composition according to any of the preceding claims 1 to 30 for inhibiting the activity of dipeptidyl peptidase IV or of analogous enzymes alone or in combination with inhibitors of the alanyl aminopeptidase or of analogous enzymes.
32. Use of at least one compound or of a pharmaceutical or cosmetic composition according to any of the preceding claims 1 to 30 for topically influencing the

activity of dipeptidyl peptidase IV or of analogous enzymes alone or in combination with inhibitors of the alanyl aminopeptidase or of analogous enzymes.

33. Use of at least one compound or of a pharmaceutical composition according to any of the preceding claims 1 to 30 for a prophylaxis and therapy of multiple sclerosis, Morbus Crohn, Colitis ulcerosa and other autoimmune diseases as well as of inflammatory diseases.
34. Use of at least one compound or of a pharmaceutical composition according to any of the preceding claims 1 to 30 for a prophylaxis and therapy of allergic asthma bronchiale and other allergic diseases.
35. Use of at least one compound or of a pharmaceutical composition according to any of the preceding claims 1 to 30 for a prophylaxis and therapy of a rejection of transplanted tissues and cells.
36. Use of at least one compound or of a pharmaceutical or cosmetic composition according to any of the preceding claims 1 to 30 for a prophylaxis and therapy of skin and mucosa diseases as, for example, psoriasis, acne as well as of dermatologic diseases associated with a hyperproliferation and changed differentiation states of fibroblasts, preferably of benign fibrosing and sclerosing skin diseases and malign fibroblastar hyperproliferation states.
37. Use of at least one compound or of a pharmaceutical composition according to any of the preceding claims 1 to 30 for a prophylaxis and therapy of acute neuronal diseases, in particular ischemia-caused cerebral damages after a ischemic or hemorrhagic stroke, craniocerebral trauma, cardiac arrest, myocardial infarct or as a consequence of heart surgery.



38. Use of at least one compound or of a pharmaceutical composition according to any of the preceding claims 1 to 30 for a prophylaxis and therapy of chronic neuronal diseases, in particular Morbus Alzheimer, Pick's disease, of the Progressive Supranuclear Palsy, of a corticobasal degeneration, of the fronto-temporal dementia, of Morbus Parkinson, in particular of Morbus Parkinson coupled to chromosome 17, of Morbus Huntington, of prion-caused diseases and of the amyotrophic lateral sclerosis.
39. Use of at least one compound or of a pharmaceutical composition according to any of the preceding claims 1 to 30 for a prophylaxis and therapy of atherosclerosis, arterial inflammation, vasculitides as well as stent restenosis, also in the form of medicament-coated stents, for example after a percutaneous transluminal angioplasty, and reperfusion syndrome.
40. Use of at least one compound or of a pharmaceutical composition according to any of the preceding claims 1 to 30 for a prophylaxis and therapy of inflammation reactions at, or caused by, medical-technical devices implanted into the organism (medical devices).
41. Use according to claim 40 in the form of a coating or a layer on the devices or a substance admixture of at least one of the compounds or compositions to the material of the devices or in the form of a local or systemic administration either successively or parallel in time.
42. Use of at least one compound or of a pharmaceutical composition according to any of the preceding claims 1 to 30 for a prophylaxis and therapy of chronic obstructive pulmonal diseases (Chronische Obstruktive Lungenerkrankungen; COPD).

43. Use of at least one compound or of a pharmaceutical composition according to any of the preceding claims 1 to 30 for a prophylaxis and therapy of prostata carcinoma and other tumors as well as of metastases.
44. Use of at least one compound or of a pharmaceutical composition according to any of the preceding claims 1 to 30 for a prophylaxis and therapy of the Heavy Acute Respiratory Syndrome (Schweres Akutes Respiratorisches Syndrom; SARS).
45. Use of at least one compound or of a pharmaceutical composition according to any of the preceding claims 1 to 30 for a prophylaxis and therapy of sepsis and sepsis-like conditions.
46. Use of at least one compound or of a pharmaceutical or cosmetic composition according to any of the preceding claims 1 to 30 for manufacturing a medicament for inhibiting the activity of dipeptidyl peptidase IV or of analogous enzymes alone or in combination with inhibitors of the alanyl aminopeptidase or of analogous enzymes.
47. Use of at least one compound or of a pharmaceutical or cosmetic composition according to any of the preceding claims 1 to 30 for manufacturing a medicament for topically influencing the activity of dipeptidyl peptidase IV or of analogous enzymes alone or in combination with inhibitors of the alanyl aminopeptidase or of analogous enzymes.
48. Use of at least one compound or of a pharmaceutical composition according to any of the preceding claims 1 to 30 for manufacturing a medicament for a prophylaxis and therapy of multiple sclerosis, Morbus Crohn, Colitis ulcerosa and other autoimmune diseases as well as of inflammatory diseases.

49. Use of at least one compound or of a pharmaceutical composition according to any of the preceding claims 1 to 30 for manufacturing a medicament for a prophylaxis and therapy of allergic asthma bronchiale and other allergic diseases.
50. Use of at least one compound or of a pharmaceutical composition according to any of the preceding claims 1 to 30 for manufacturing a medicament for a prophylaxis and therapy of a rejection of transplanted tissues and cells.
51. Use of at least one compound or of a pharmaceutical or cosmetic composition according to any of the preceding claims 1 to 30 for manufacturing a medicament for a prophylaxis and therapy of skin and mucosa diseases as, for example, psoriasis, acne as well as of dermatologic diseases associated with a hyperproliferation and changed differentiation states of fibroblasts, preferably of benign fibrosing and sclerosing skin diseases and malign fibroblastar hyperproliferation states.
52. Use of at least one compound or of a pharmaceutical composition according to any of the preceding claims 1 to 30 for manufacturing a medicament for a prophylaxis and therapy of acute neuronal diseases, in particular ischemia-caused cerebral damages after a ischemic or hemorrhagic stroke, craniocerebral trauma, cardiac arrest, myocardial infarct or as a consequence of heart surgery.
53. Use of at least one compound or of a pharmaceutical composition according to any of the preceding claims 1 to 30 for manufacturing a medicament for a prophylaxis and therapy of chronic neuronal diseases, in particular Morbus Alzheimer, Pick's disease, of the Progressive Supranuclear Palsy, of a corticobasal degeneration, of the frontotemporal dementia, of Morbus Parkinson,

in particular of Morbus Parkinson coupled to chromosome 17, of Morbus Huntington, of prion-caused diseases and of the amyotrophic lateral sclerosis.

54. Use of at least one compound or of a pharmaceutical composition according to any of the preceding claims 1 to 30 for manufacturing a medicament for a prophylaxis and therapy of atherosclerosis, arterial inflammation, vasculitides as well as stent restenosis, also in the form of medicament-coated stents, for example after a percutaneous transluminal angioplasty, and reperfusion syndrome.
55. Use of at least one compound or of a pharmaceutical composition according to any of the preceding claims 1 to 30 for manufacturing a medicament for a prophylaxis and therapy of inflammation reactions at, or caused by, medical-technical devices implanted into the organism (medical devices).
56. Use according to claim 55 in the form of a coating or a layer on the devices or a substance admixture of at least one of the compounds or compositions to the material of the devices or in the form of a local or systemic administration either successively or parallel in time.
57. Use of at least one compound or of a pharmaceutical composition according to any of the preceding claims 1 to 30 for manufacturing a medicament for a prophylaxis and therapy of chronic obstructive pulmonary diseases (Chronische Obstruktive Lungenerkrankungen; COPD).
58. Use of at least one compound or of a pharmaceutical composition according to any of the preceding claims 1 to 30 for manufacturing a medicament for a prophylaxis and therapy of prostata carcinoma and other tumors as well as of metastases.

59. Use of at least one compound or of a pharmaceutical composition according to any of the preceding claims 1 to 30 for manufacturing a medicament for a prophylaxis and therapy of the Heavy Acute Respiratory Syndrome (Schweres Akutes Respiratorisches Syndrom; SARS).
60. Use of at least one compound or of a pharmaceutical composition according to any of the preceding claims 1 to 30 for manufacturing a medicament for a prophylaxis and therapy of sepsis and sepsis-like conditions.
61. A process for inhibiting the activity of alanyl aminopeptidases or of analogous enzymes alone or in combination with inhibitors of dipeptidyl peptidase IV or of analogous enzymes by an administration of at least one compound of pharmaceutical or cosmetic composition according to any of the preceding claims 1 to 30 in an amount required for an inhibition of the enzyme activity.
62. A process for topically influencing the activity of alanyl aminopeptidases or of analogous enzymes alone or in combination with inhibitors of dipeptidyl peptidase IV or of analogous enzymes by an administration of at least one compound or pharmaceutical or cosmetic composition according to any of the preceding claims 1 to 30 in an amount required for influencing the enzyme activity.
63. A process for a prophylaxis and therapy of multiple sclerosis, Morbus Crohn, Colitis ulcerosa and other autoimmune diseases as well as of inflammatory diseases by an administration of at least one compound or pharmaceutical composition according to any of the preceding claims 1 to 30 in an amount required for a prophylactic or therapeutic treatment.
64. A process for a prophylaxis and therapy of asthma bronchiale and other allergic diseases by an administration of at least one compound or pharmaceutical

composition according to any of the preceding claims 1 to 30 in an amount required for a prophylactic or therapeutic treatment.

65. A process for a prophylaxis and therapy of a rejection of transplanted tissues and cells as, for example, allogenic kidney or stem cell transplantation by an administration of at least one compound or pharmaceutical composition according to any of the preceding claims 1 to 30 in an amount required for a prophylactic or therapeutic treatment.
66. A process for a prophylaxis and therapy of skin and mucosa diseases as, for example, psoriasis, acne as well as of dermatologic diseases associated with a hyperproliferation and changed differentiation states of fibroblasts, of benign fibrosing and sclerosing skin diseases and malign fibroblastar hyperproliferation states by an administration of at least one compound or pharmaceutical composition according to any of the preceding claims 1 to 30 in an amount required for a prophylactic or therapeutic treatment.
67. A process for a prophylaxis and therapy of acute neuronal diseases, in particular ischemia-caused cerebral damages after a ischemic or hemorrhagic stroke, craniocerebral trauma, cardiac arrest, myocardial infarct or as a consequence of heart surgery by an administration of at least one compound or pharmaceutical composition according to any of the preceding claims 1 to 30 in an amount required for a prophylactic or therapeutic treatment.
68. A process for a prophylaxis and therapy of chronic neuronal diseases, in particular Morbus Alzheimer, Pick's disease, of the Progressive Supranuclear Palsy, of a corticobasal degeneration, of the frontotemporal dementia, of Morbus Parkinson, in particular of Morbus Parkinson coupled to chromosome 17, of Morbus Huntington, of prion-caused diseases and of the amyotrophic lateral sclerosis by an administration of at least one compound or pharmaceuti-

cal composition according to any of the preceding claims 1 to 30 in an amount required for a prophylactic or therapeutic treatment.

69. A process for a prophylaxis and therapy of atherosclerosis, arterial inflammation, stent restenosis, also in the form of medicament-coated stents, for example after a percutaneous transluminal angioplasty, and reperfusion syndrome by an administration of at least one compound or pharmaceutical composition according to any of the preceding claims 1 to 30 in an amount required for a prophylactic or therapeutic treatment.
70. A process for a prophylaxis and therapy of inflammation reactions at, or caused by, medical-technical devices implanted into the organism (medical devices) by an administration of at least one compound or pharmaceutical composition according to any of the preceding claims 1 to 30 in an amount required for a prophylactic or therapeutic treatment.
71. The process according to claim 70, wherein the administration is effected in the form of a local or systemic administration, either successively or parallel in time, of at least one compound or pharmaceutical composition according to any of the preceding claims 1 to 30.
72. A process according to claim 70, wherein the administration is effected by the application of a coating or layer, on the devices, of at least one compound or composition according to any of the preceding claims 1 to 30 or of a substance admixture of at least one compound or composition according to any of the preceding claims 1 to 30 to the material of the devices.
73. A process for a prophylaxis and therapy of chronic obstructive pulmonary diseases (Chronische Obstruktive Lungenerkrankungen; COPD) by an administration of at least one compound or pharmaceutical composition according to

any of the preceding claims 1 to 30 in an amount required for a prophylactic or therapeutic treatment.

74. A process for a prophylaxis and therapy of prostata carcinoma and other tumors as well as of metastases by an administration of at least one compound or pharmaceutical composition according to any of the preceding claims 1 to 30 in an amount required for a prophylactic or therapeutic treatment.
75. A process for a prophylaxis and therapy of the Heavy Acute Respiratory Syndrome (Schweres Akutes Respiratorisches Syndrom; SARS) by an administration of at least one compound or pharmaceutical composition according to any of the preceding claims 1 to 30 in an amount required for a prophylactic or therapeutic treatment.
76. A process for a prophylaxis and therapy of sepsis and sepsis-like conditions by an administration of at least one compound or pharmaceutical composition according to any of the preceding claims 1 to 30 in an amount required for a prophylactic or therapeutic treatment.